Polly A. Niravath, MD

Associate Professor of Clinical Medicine in Oncology, Academic Institute
Houston Methodist
Weill Cornell Medical College


Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
Anand, K, Patel, T, Niravath, P, Rodriguez, A, Darcourt, J, Belcheva, A, Boone, T, Ensor, J & Chang, J 2021, , Scientific Reports, vol. 11, no. 1, 82. https://doi.org/10.1038/s41598-020-80081-y

ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer
Koca, E, Niravath, PA, Ensor, J, Patel, TA, Li, X, Hemati, P, Wong, H, Qian, W, Boone, T, Zhao, J, Ramshesh, PV, Cohen, AL, Murthy, A, Nair, S, Darcourt, JG, Belcheva, A, Kaklamani, VG & Chang, JCN 2021, , Breast Cancer Research and Treatment, vol. 188, no. 2, pp. 433-439. https://doi.org/10.1007/s10549-021-06214-7

Measuring Ovarian Escape in Premenopausal Estrogen Receptor-Positive Breast Cancer Patients on Ovarian Suppression Therapy
Burns, E, Koca, E, Xu, J, McLean, E, Lee, R, Patel, T, Chang, J & Niravath, P 2021, , Oncologist, vol. 26, no. 6, pp. e936-e942. https://doi.org/10.1002/onco.13722

The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast
Lewis, GD, Haque, W, Farach, A, Hatch, SS, Brian Butler, E, Niravath, PA, Schwartz, MR, Bonefas, E & Teh, BS 2021, , Reports of Practical Oncology and Radiotherapy, vol. 26, no. 2, pp. 179-187. https://doi.org/10.5603/RPOR.a2021.0026

Pulmonary arterial hypertension in breast cancer patients on HER2-targeted therapy: A review of FDA adverse events reporting system data
Umoru, G, Taitano, M, Beshay, S, Niravath, P & Sahay, S 2020, , ERJ Open Research, vol. 6, no. 2, 00199-2020, pp. 1-3. https://doi.org/10.1183/23120541.00199-2020

TBCRC023: A randomized phase II neoadjuvant trial of lapatinib plus trastuzumab without chemotherapy for 12 versus 24 weeks in patients with HER2-positive breast cancer
on behalf of the Translational Breast Cancer Research Consortium 2020, , Clinical Cancer Research, vol. 26, no. 4, pp. 821-827. https://doi.org/10.1158/1078-0432.CCR-19-0851

Comparison of outcomes between metaplastic and triple-negative breast cancer patients
Polamraju, P, Haque, W, Cao, K, Verma, V, Schwartz, M, Klimberg, VS, Hatch, S, Niravath, P, Butler, EB & Teh, BS 2020, , Breast, vol. 49, pp. 8-16. https://doi.org/10.1016/j.breast.2019.10.003

A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer
Anand, K, Niravath, P, Patel, T, Ensor, J, Rodriguez, A, Boone, T, Wong, ST & Chang, JC 2021, , Clinical Breast Cancer, vol. 21, no. 3, pp. 199-204. https://doi.org/10.1016/j.clbc.2020.09.015

Omission of radiation therapy following breast conservation in older (=70 years) women with T1-2N0 triple-negative breast cancer
Haque, WM, Verma, V, Hsiao, KY, Hatch, S, Arentz, C, Szeja, S, Schwartz, M, Niravath, PA, Bonefas, E, Miltenburg, D, Butler, EB & Teh, BS 2019, , Breast Journal, vol. 25, no. 6, pp. 1126-1133. https://doi.org/10.1111/tbj.13443

Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia
Niravath, PA, Hilsenbeck, SG, Wang, T, Jiralerspong, S, Nangia, J, Pavlick, A, Ademuyiwa, F, Frith, A, Ma, C, Park, H, Rigden, C, Suresh, R, Ellis, M, Kent Osborne, C & Rimawi, MF 2019, , Breast Cancer Research and Treatment, vol. 177, no. 2, pp. 427-435. https://doi.org/10.1007/s10549-019-05319-4

A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Patel, T, Ensor, Jr. JE, Creamer, SL, Boone, T, Rodriguez, AA, Niravath, PA, Darcourt, J, Meisel, JL, Li, X, Zhao, J, Kuhn, JG, Rosato, RR, Qian, W, Belcheva, A, Schwartz, MR, Kaklamani, VG & Chang, JC 2019, , Breast Cancer Research, vol. 21, no. 1, 100. https://doi.org/10.1186/s13058-019-1186-0

Acupuncture and Vitamin D for the Management of Aromatase Inhibitor-Induced Arthralgia
Anand, K & Niravath, P 2019, , Current Oncology Reports, vol. 21, no. 6, 51. https://doi.org/10.1007/s11912-019-0795-1

TBCRC 022: A phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases
Freedman, RA, Gelman, RS, Anders, CK, Melisko, ME, Parsons, HA, Cropp, AM, Silvestri, K, Cotter, CM, Componeschi, KP, Marte, JM, Connolly, RM, Moy, B, Van Poznak, CH, Blackwell, KL, Puhalla, SL, Jankowitz, RC, Smith, KL, Ibrahim, N, Moynihan, TJ, OSullivan, CC, Nangia, J, Niravath, PA, Tung, N, Pohlmann, PR, Burns, R, Rimawi, MF, Krop, IE, Wolff, AC, Winer, EP & Lin, NU 2019, , Journal of Clinical Oncology, vol. 37, no. 13, pp. 1081-1089. https://doi.org/10.1200/JCO.18.01511

A Behavior-Modification, Clinical-Grade Mobile Application to Improve Breast Cancer Survivors' Accountability and Health Outcomes
Stubbins, R, He, T, Yu, X, Puppala, M, Ezeana, CF, Chen, S, Valdivia y Alvarado, M, Ensor, J, Rodriguez, A, Niravath, P, Chang, J, Wong, STC & Patel, T 2018, , JCO Clinical Cancer Informatics, no. 2, pp. 1-11. https://doi.org/10.1200/CCI.18.00054

Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis
Ayyagari, R, Tang, D, Patterson-Lomba, O, Zhou, Z, Xie, J, Chandiwana, D, Dalal, AA & Niravath, PA 2018, , Current Medical Research and Opinion, vol. 34, no. 9, pp. 1645-1652. https://doi.org/10.1080/03007995.2018.1479246

Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2- Advanced Breast Cancer
Dalal, AA, Gauthier, G, Gagnon-Sanschagrin, P, Burne, R, Guérin, A, Niravath, P & Small, T 2018, , Advances in Therapy, vol. 35, no. 9, pp. 1356-1367. https://doi.org/10.1007/s12325-018-0764-3

Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer
Guérin, A, Goldschmidt, D, Small, T, Gagnon-Sanschagrin, P, Romdhani, H, Gauthier, G, Kelkar, S, Wu, EQ, Niravath, P & Dalal, AA 2018, , Advances in Therapy, vol. 35, no. 8, pp. 1251-1264. https://doi.org/10.1007/s12325-018-0740-y

Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer
Dalal, AA, Gagnon-Sanschagrin, P, Burne, R, Guérin, A, Gauthier, G, Small, T & Niravath, P 2018, , Advances in Therapy, vol. 35, no. 6, pp. 768-778. https://doi.org/10.1007/s12325-018-0701-5

Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2– Metastatic Breast Cancer:: A Network Meta-analysis
Ayyagari, R, Tang, D, Patterson-Lomba, O, Zhou, Z, Xie, J, Chandiwana, D, Dalal, AA & Niravath, PA 2018, , Clinical Therapeutics, vol. 40, no. 4, pp. 628-639.e3. https://doi.org/10.1016/j.clinthera.2018.03.004

Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study
Goldschmidt, D, Dalal, AA, Romdhani, H, Kelkar, S, Guerin, A, Gauthier, G, Wu, EQ, Niravath, P & Small, T 2018, , Advances in Therapy, vol. 35, no. 4, pp. 482-493. https://doi.org/10.1007/s12325-018-0676-2